;PMID: 11510894
;source_file_975.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..131] = [t:44..131]
;2)section:[e:135..170] = [t:135..170]
;3)section:[e:174..296] = [t:174..296]
;4)sentence:[e:300..543] = [t:300..543]
;5)sentence:[e:544..756] = [t:544..756]
;6)sentence:[e:757..990] = [t:757..990]
;7)sentence:[e:991..1224] = [t:991..1224]
;8)sentence:[e:1225..1385] = [t:1225..1385]
;9)sentence:[e:1386..1557] = [t:1386..1557]
;10)sentence:[e:1558..1744] = [t:1558..1744]
;11)sentence:[e:1745..1819] = [t:1745..1819]
;12)sentence:[e:1820..2002] = [t:1820..2002]
;13)sentence:[e:2003..2235] = [t:2003..2235]
;14)section:[e:2239..2284] = [t:2239..2284]
;Token/POS Errors
;ERROR_Token in entity file but not tree[866..870] i.e.
;ERROR_Token in tree file but not entity[865..870]  i.e.

;section 0 Span:0..38
;Pflugers Arch. 2001 Jul;442(4):603-13.
(SEC
  (FRAG (NNP:[0..8] Pflugers) (NNP:[9..13] Arch) (.:[13..14] .)
        (CD:[15..19] 2001) (CC:[20..28] Jul;442-LRB-) (CD:[28..30] 4-RRB-)
        (CD:[30..34] :603) (HYPH:[34..35] -) (CD:[35..37] 13) (.:[37..38] .)))

;sentence 1 Span:44..131
;Fatty acids inhibit anion secretion in rat colon: apical and basolateral
;action  sites.
;[44..55]:substance:"Fatty acids"
;[64..69]:substance:"anion"
(SENT
  (UCP-HLN
    (S
      (NP-SBJ (JJ:[44..49] Fatty) (NNS:[50..55] acids))
      (VP (VBP:[56..63] inhibit)
        (NP (NN:[64..69] anion) (NN:[70..79] secretion))
        (PP-LOC (IN:[80..82] in)
          (NP (NN:[83..86] rat) (NN:[87..92] colon)))))
    (::[92..93] :)
    (NP
      (NP (JJ:[94..100] apical)
        (NML-1 (-NONE-:[100..100] *P*)))
      (CC:[101..104] and)
      (NP (JJ:[105..116] basolateral)
        (NML-1 (NN:[117..123] action) (NNS:[125..130] sites))))
    (.:[130..131] .)))

;section 2 Span:135..170
;Schultheiss G, Ribeiro R, Diener M.
(SEC
  (FRAG (NNP:[135..146] Schultheiss) (NNP:[147..148] G) (,:[148..149] ,)
        (NNP:[150..157] Ribeiro) (NNP:[158..160] R,) (NNP:[161..167] Diener)
        (NNP:[168..170] M.)))

;section 3 Span:174..296
;Institut fur Veterinar-Physiologie, Justus-Liebig-Universitat Giessen,
;Germany.  gerhard.schultheiss@vetmed.uni-giessen.de
(SEC
  (FRAG (NNP:[174..182] Institut) (NN:[183..186] fur) (NN:[187..196] Veterinar)
        (HYPH:[196..197] -) (NNP:[197..208] Physiologie) (,:[208..209] ,)
        (NNP:[210..216] Justus) (HYPH:[216..217] -) (NNP:[217..223] Liebig)
        (HYPH:[223..224] -) (NNP:[224..235] Universitat)
        (NNP:[236..243] Giessen) (,:[243..244] ,) (NNP:[245..252] Germany)
        (.:[252..253] .) ('':[255..262] gerhard)
        (VBD:[262..281] .schultheiss@vetmed) (CD:[281..285] .uni)
        (HYPH:[285..286] -) (JJ:[286..293] giessen) (NN:[293..296] .de)))

;sentence 4 Span:300..543
;Ca2+-dependent secretagogues evoke only a transient Cl- secretion in
;intestinal  epithelia, although they induce a prolonged increase in the
;intracellular Ca2+  concentration, suggesting that they may exert an
;additional antisecretory  action.
;[300..304]:substance:"Ca2+"
;[315..328]:substance:"secretagogues"
;[352..355]:substance:"Cl-"
;[455..459]:substance:"Ca2+"
(SENT
  (S
    (NP-SBJ
      (ADJP
        (NML (NN:[300..303] Ca2) (SYM:[303..304] +))
        (HYPH:[304..305] -) (JJ:[305..314] dependent))
      (NNS:[315..328] secretagogues))
    (VP (VBP:[329..334] evoke)
      (NP (RB:[335..339] only) (DT:[340..341] a) (JJ:[342..351] transient)
         (NN:[352..354] Cl) (SYM:[354..355] -)
        (NN:[356..365] secretion))
      (PP-LOC (IN:[366..368] in)
        (NP (JJ:[369..379] intestinal) (NNS:[381..390] epithelia)))
      (,:[390..391] ,)
      (SBAR-ADV (IN:[392..400] although)
        (S
          (NP-SBJ (PRP:[401..405] they))
          (VP (VBP:[406..412] induce)
            (NP (DT:[413..414] a) (VBN:[415..424] prolonged)
                (NN:[425..433] increase))
            (PP (IN:[434..436] in)
              (NP (DT:[437..440] the) (JJ:[441..454] intracellular)
                (NML (NN:[455..458] Ca2) (SYM:[458..459] +))
                (NN:[461..474] concentration)))
            (,:[474..475] ,)
            (S-ADV
              (NP-SBJ (-NONE-:[475..475] *))
              (VP (VBG:[476..486] suggesting)
                (SBAR (IN:[487..491] that)
                  (S
                    (NP-SBJ (PRP:[492..496] they))
                    (VP (MD:[497..500] may)
                      (VP (VB:[501..506] exert)
                        (NP (DT:[507..509] an) (JJ:[510..520] additional)
                            (JJ:[521..534] antisecretory) (NN:[536..542] action))))))))))))
    (.:[542..543] .)))

;sentence 5 Span:544..756
;In order to study the mechanism of this antisecretory effect, Cl-  secretion,
;measured as the increase in short-circuit current (Isc), was evoked  by
;carbachol in the absence and presence of different inhibitors.
;[606..609]:substance:"Cl-"
;[650..671]:quantitative-name:"short-circuit current"
;[673..676]:quantitative-name:"Isc"
;[694..703]:substance:"carbachol"
;[745..755]:substance:"inhibitors"
(SENT
  (S
    (SBAR-ADV (IN:[544..546] In) (NN:[547..552] order)
      (S
        (NP-SBJ (-NONE-:[552..552] *))
        (VP (TO:[553..555] to)
          (VP (VB:[556..561] study)
            (NP
              (NP (DT:[562..565] the) (NN:[566..575] mechanism))
              (PP (IN:[576..578] of)
                (NP (DT:[579..583] this) (JJ:[584..597] antisecretory)
                    (NN:[598..604] effect))))))))
    (,:[604..605] ,)
    (NP-SBJ-1
      (NP
         (NN:[606..608] Cl) (SYM:[608..609] -)
        (NN:[611..620] secretion))
      (,:[620..621] ,)
      (VP (VBN:[622..630] measured)
        (NP (-NONE-:[630..630] *))
        (PP (IN:[631..633] as)
          (NP
            (NP
              (NP (DT:[634..637] the) (NN:[638..646] increase))
              (PP (IN:[647..649] in)
                (NP
                  (NML (JJ:[650..655] short) (HYPH:[655..656] -)
                       (NN:[656..663] circuit))
                  (NN:[664..671] current))))
            (NP (-LRB-:[672..673] -LRB-) (NN:[673..676] Isc)
                (-RRB-:[676..677] -RRB-))))))
    (,:[677..678] ,)
    (VP (VBD:[679..682] was)
      (VP (VBN:[683..689] evoked)
        (NP-1 (-NONE-:[689..689] *))
        (PP (IN:[691..693] by)
          (NP-LGS (NN:[694..703] carbachol)))
        (PP (IN:[704..706] in)
          (NP
            (NP (DT:[707..710] the) (NN:[711..718] absence) (CC:[719..722] and)
                (NN:[723..731] presence))
            (PP (IN:[732..734] of)
              (NP (JJ:[735..744] different) (NNS:[745..755] inhibitors)))))))
    (.:[755..756] .)))

;sentence 6 Span:757..990
;Neither a  calmodulin antagonist, calmidazolium, nor different inhibitors of
;the nitric  oxide (NO) pathway, i.e. Nomega-nitro-L-arginine (L-NNA) and 
;Nomega-nitro-L-arginine methylester (L-NAME), affected the carbachol-induced 
;Isc.
;[768..778]:substance:"calmodulin"
;[779..789]:substance:"antagonist"
;[791..804]:substance:"calmidazolium"
;[820..830]:substance:"inhibitors"
;[838..851]:substance:"nitric  oxide"
;[853..855]:substance:"NO"
;[871..894]:substance:"Nomega-nitro-L-arginine"
;[896..901]:substance:"L-NNA"
;[908..943]:substance:"Nomega-nitro-L-arginine methylester"
;[945..951]:substance:"L-NAME"
;[967..976]:substance:"carbachol"
;[986..989]:quantitative-name:"Isc"
(SENT
  (S
    (NP-SBJ (CC:[757..764] Neither)
      (NP
        (NP (DT:[765..766] a) (NN:[768..778] calmodulin)
            (NN:[779..789] antagonist))
        (,:[789..790] ,)
        (NP (NN:[791..804] calmidazolium)))
      (,:[804..805] ,) (CC:[806..809] nor)
      (NP
        (NP
          (NP (JJ:[810..819] different) (NNS:[820..830] inhibitors))
          (PP (IN:[831..833] of)
            (NP (DT:[834..837] the)
              (NML
                (NML (JJ:[838..844] nitric) (NN:[846..851] oxide))
                (NML (-LRB-:[852..853] -LRB-) (NN:[853..855] NO)
                     (-RRB-:[855..856] -RRB-)))
              (NN:[857..864] pathway))))
        (,:[864..865] ,)
        (NP
          (ADVP (FW:[865..870] i.e.))
          (NP
            (NP (NN:[871..894] Nomega-nitro-L-arginine))
            (NP (-LRB-:[895..896] -LRB-) (NN:[896..901] L-NNA)
                (-RRB-:[901..902] -RRB-)))
          (CC:[903..906] and)
          (NP
            (NP (NN:[908..931] Nomega-nitro-L-arginine)
                (NN:[932..943] methylester))
            (NP (-LRB-:[944..945] -LRB-) (NN:[945..951] L-NAME)
                (-RRB-:[951..952] -RRB-))))))
    (,:[952..953] ,)
    (VP (VBD:[954..962] affected)
      (NP (DT:[963..966] the)
        (ADJP (NN:[967..976] carbachol) (HYPH:[976..977] -)
              (VBN:[977..984] induced))
        (NN:[986..989] Isc)))
    (.:[989..990] .)))

;sentence 7 Span:991..1224
;However, inhibition of phospholipases A2 (PLA2) by quinacrine or 
;arachidonyltrifluoromethyl ketone (AACOCF3) enhanced the Isc response evoked
;by  carbachol, suggesting a role of fatty acids in the downregulation of
;anion  secretion.
;[1014..1031]:substance:"phospholipases A2"
;[1033..1037]:substance:"PLA2"
;[1042..1052]:substance:"quinacrine"
;[1057..1090]:substance:"arachidonyltrifluoromethyl ketone"
;[1092..1099]:substance:"AACOCF3"
;[1114..1117]:quantitative-name:"Isc"
;[1138..1147]:substance:"carbachol"
;[1170..1181]:substance:"fatty acids"
;[1207..1212]:substance:"anion"
(SENT
  (S
    (ADVP (RB:[991..998] However))
    (,:[998..999] ,)
    (NP-SBJ
      (NP (NN:[1000..1010] inhibition))
      (PP (IN:[1011..1013] of)
        (NP
          (NP (NNS:[1014..1028] phospholipases) (NN:[1029..1031] A2))
          (NP (-LRB-:[1032..1033] -LRB-) (NN:[1033..1037] PLA2)
              (-RRB-:[1037..1038] -RRB-))))
      (PP (IN:[1039..1041] by)
        (NP
          (NP (NN:[1042..1052] quinacrine))
          (CC:[1053..1055] or)
          (NP
            (NP (NN:[1057..1083] arachidonyltrifluoromethyl)
                (NN:[1084..1090] ketone))
            (NP (-LRB-:[1091..1092] -LRB-) (NN:[1092..1099] AACOCF3)
                (-RRB-:[1099..1100] -RRB-))))))
    (VP (VBD:[1101..1109] enhanced)
      (NP
        (NP (DT:[1110..1113] the) (NN:[1114..1117] Isc)
            (NN:[1118..1126] response))
        (VP (VBN:[1127..1133] evoked)
          (NP (-NONE-:[1133..1133] *))
          (PP (IN:[1134..1136] by)
            (NP-LGS (NN:[1138..1147] carbachol)))))
      (,:[1147..1148] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1148..1148] *))
        (VP (VBG:[1149..1159] suggesting)
          (NP
            (NP (DT:[1160..1161] a) (NN:[1162..1166] role))
            (PP (IN:[1167..1169] of)
              (NP (JJ:[1170..1175] fatty) (NNS:[1176..1181] acids)))
            (PP (IN:[1182..1184] in)
              (NP
                (NP (DT:[1185..1188] the) (NN:[1189..1203] downregulation))
                (PP (IN:[1204..1206] of)
                  (NP (NN:[1207..1212] anion) (NN:[1214..1223] secretion)))))))))
    (.:[1223..1224] .)))

;sentence 8 Span:1225..1385
;Neither econazole, a cytochrome P450 inhibitor, nor  nordihydroguaiaretic
;acid (NDGA), an inhibitor of lipoxygenases, mimicked the  action of the PLA2
;blockers.
;[1233..1242]:substance:"econazole"
;[1246..1261]:cyp450:"cytochrome P450"
;[1262..1271]:substance:"inhibitor"
;[1278..1303]:substance:"nordihydroguaiaretic acid"
;[1305..1309]:substance:"NDGA"
;[1315..1324]:substance:"inhibitor"
;[1328..1341]:substance:"lipoxygenases"
;[1371..1375]:substance:"PLA2"
;[1376..1384]:substance:"blockers"
(SENT
  (S
    (NP-SBJ (CC:[1225..1232] Neither)
      (NP
        (NP (NN:[1233..1242] econazole))
        (,:[1242..1243] ,)
        (NP (DT:[1244..1245] a)
          (NML (NN:[1246..1256] cytochrome) (NN:[1257..1261] P450))
          (NN:[1262..1271] inhibitor)))
      (,:[1271..1272] ,) (CC:[1273..1276] nor)
      (NP
        (NP
          (NP (JJ:[1278..1298] nordihydroguaiaretic) (NN:[1299..1303] acid))
          (NP (-LRB-:[1304..1305] -LRB-) (NN:[1305..1309] NDGA)
              (-RRB-:[1309..1310] -RRB-)))
        (,:[1310..1311] ,)
        (NP
          (NP (DT:[1312..1314] an) (NN:[1315..1324] inhibitor))
          (PP (IN:[1325..1327] of)
            (NP (NNS:[1328..1341] lipoxygenases))))))
    (,:[1341..1342] ,)
    (VP (VBD:[1343..1351] mimicked)
      (NP
        (NP (DT:[1352..1355] the) (NN:[1357..1363] action))
        (PP (IN:[1364..1366] of)
          (NP (DT:[1367..1370] the) (NN:[1371..1375] PLA2)
              (NNS:[1376..1384] blockers)))))
    (.:[1384..1385] .)))

;sentence 9 Span:1386..1557
;Conversely, short- or medium-chain fatty acids  inhibited the carbachol- and
;forskolin-induced Isc with caprate (C10:0) being  the most efficient
;water-soluble fatty acid.
;[1421..1432]:substance:"fatty acids"
;[1448..1457]:substance:"carbachol"
;[1463..1472]:substance:"forskolin"
;[1481..1484]:quantitative-name:"Isc"
;[1490..1497]:substance:"caprate"
;[1499..1504]:substance:"C10:0"
;[1532..1537]:substance:"water"
;[1546..1556]:substance:"fatty acid"
(SENT
  (S
    (ADVP (RB:[1386..1396] Conversely))
    (,:[1396..1397] ,)
    (NP-SBJ
      (NP
        (NML (JJ:[1398..1403] short) (HYPH:[1403..1404] -)
          (NML-3 (-NONE-:[1404..1404] *P*)))
        (NML-4 (-NONE-:[1404..1404] *P*)))
      (CC:[1405..1407] or)
      (NP
        (NML (JJ:[1408..1414] medium) (HYPH:[1414..1415] -)
          (NML-3 (NN:[1415..1420] chain)))
        (NML-4 (JJ:[1421..1426] fatty) (NNS:[1427..1432] acids))))
    (VP (VBD:[1434..1443] inhibited)
      (NP (DT:[1444..1447] the)
        (NML
          (NML
            (ADJP (NN:[1448..1457] carbachol) (HYPH:[1457..1458] -)
              (ADJP-2 (-NONE-:[1458..1458] *P*)))
            (NML-1 (-NONE-:[1458..1458] *P*)))
          (CC:[1459..1462] and)
          (NML
            (ADJP (NN:[1463..1472] forskolin) (HYPH:[1472..1473] -)
              (ADJP-2 (VBN:[1473..1480] induced)))
            (NML-1 (NN:[1481..1484] Isc)))))
      (PP (IN:[1485..1489] with)
        (NP
          (NP
            (NP (NN:[1490..1497] caprate))
            (NP (-LRB-:[1498..1499] -LRB-) (NN:[1499..1504] C10:0)
                (-RRB-:[1504..1505] -RRB-)))
          (VP (VBG:[1506..1511] being)
            (NP-PRD (DT:[1513..1516] the)
              (ADJP (RBS:[1517..1521] most) (JJ:[1522..1531] efficient))
              (ADJP (NN:[1532..1537] water) (HYPH:[1537..1538] -)
                    (JJ:[1538..1545] soluble))
               (JJ:[1546..1551] fatty) (NN:[1552..1556] acid))))))
    (.:[1556..1557] .)))

;sentence 10 Span:1558..1744
;This fatty acid inhibited a Cl-  current, which was driven across the apical
;membrane by a serosally to mucosally  directed Cl- gradient after
;depolarization of the basolateral membrane.
;[1563..1573]:substance:"fatty acid"
;[1586..1589]:substance:"Cl-"
;[1682..1685]:substance:"Cl-"
(SENT
  (S
    (NP-SBJ (DT:[1558..1562] This)
       (JJ:[1563..1568] fatty) (NN:[1569..1573] acid))
    (VP (VBD:[1574..1583] inhibited)
      (NP
        (NP (DT:[1584..1585] a)
           (NN:[1586..1588] Cl) (SYM:[1588..1589] -)
          (NN:[1591..1598] current))
        (,:[1598..1599] ,)
        (SBAR
          (WHNP-1 (WDT:[1600..1605] which))
          (S
            (NP-SBJ-1 (-NONE-:[1605..1605] *T*))
            (VP (VBD:[1606..1609] was)
              (VP (VBN:[1610..1616] driven)
                (NP-1 (-NONE-:[1616..1616] *))
                (PP (IN:[1617..1623] across)
                  (NP (DT:[1624..1627] the) (JJ:[1628..1634] apical)
                      (NN:[1635..1643] membrane)))
                (PP (IN:[1644..1646] by)
                  (NP-LGS (DT:[1647..1648] a)
                    (ADJP
                      (ADVP (RB:[1649..1658] serosally)
                        (PP (TO:[1659..1661] to)
                          (ADVP (RB:[1662..1671] mucosally))))
                      (VBN:[1673..1681] directed))
                     (NN:[1682..1684] Cl) (SYM:[1684..1685] -)
                    (NN:[1686..1694] gradient)))
                (PP-TMP (IN:[1695..1700] after)
                  (NP
                    (NP (NN:[1701..1715] depolarization))
                    (PP (IN:[1716..1718] of)
                      (NP (DT:[1719..1722] the) (JJ:[1723..1734] basolateral)
                          (NN:[1735..1743] membrane)))))))))))
    (.:[1743..1744] .)))

;sentence 11 Span:1745..1819
;A second  action site of fatty acids seems to be the basolateral membrane.
;[1770..1781]:substance:"fatty acids"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1745..1746] A) (JJ:[1747..1753] second) (NN:[1755..1761] action)
          (NN:[1762..1766] site))
      (PP (IN:[1767..1769] of)
        (NP (JJ:[1770..1775] fatty) (NNS:[1776..1781] acids))))
    (VP (VBZ:[1782..1787] seems)
      (S
        (NP-SBJ-1 (-NONE-:[1787..1787] *))
        (VP (TO:[1788..1790] to)
          (NP (VB:[1791..1793] be)
            (NP-PRD (DT:[1794..1797] the) (JJ:[1798..1809] basolateral)
                    (NN:[1810..1818] membrane))))))
    (.:[1818..1819] .)))

;sentence 12 Span:1820..2002
;After  permeabilization of the apical membrane with the ionophore nystatin, a
;mucosally  to serosally directed K+ gradient induced a K+ current, which was
;also inhibited  by caprate.
;[1876..1885]:substance:"ionophore"
;[1886..1894]:substance:"nystatin"
;[1931..1933]:substance:"K+"
;[1953..1955]:substance:"K+"
;[1994..2001]:substance:"caprate"
(SENT
  (S
    (PP-TMP (IN:[1820..1825] After)
      (NP
        (NP (NN:[1827..1843] permeabilization))
        (PP (IN:[1844..1846] of)
          (NP (DT:[1847..1850] the) (JJ:[1851..1857] apical)
              (NN:[1858..1866] membrane)))
        (PP (IN:[1867..1871] with)
          (NP (DT:[1872..1875] the) (NN:[1876..1885] ionophore)
              (NN:[1886..1894] nystatin)))))
    (,:[1894..1895] ,)
    (NP-SBJ (DT:[1896..1897] a)
      (ADJP
        (ADVP (RB:[1898..1907] mucosally)
          (PP (TO:[1909..1911] to)
            (ADVP (RB:[1912..1921] serosally))))
        (VBN:[1922..1930] directed))
      (NML (NN:[1931..1932] K) (SYM:[1932..1933] +))
      (NN:[1934..1942] gradient))
    (VP (VBD:[1943..1950] induced)
      (NP
        (NP (DT:[1951..1952] a)
          (NML (NN:[1953..1954] K) (SYM:[1954..1955] +))
          (NN:[1956..1963] current))
        (,:[1963..1964] ,)
        (SBAR
          (WHNP-1 (WDT:[1965..1970] which))
          (S
            (NP-SBJ-1 (-NONE-:[1970..1970] *T*))
            (VP (VBD:[1971..1974] was)
              (ADVP (RB:[1975..1979] also))
              (VP (VBN:[1980..1989] inhibited)
                (NP-1 (-NONE-:[1989..1989] *))
                (PP (IN:[1991..1993] by)
                  (NP-LGS (NN:[1994..2001] caprate)))))))))
    (.:[2001..2002] .)))

;sentence 13 Span:2003..2235
;These results indicate that carbachol not only acts as a  secretagogue but at
;the same time initializes downregulation by increasing the  intracellular
;concentration of fatty acids, a mechanism limiting the resulting  Cl-
;secretion.
;[2031..2040]:substance:"carbachol"
;[2061..2073]:substance:"secretagogue"
;[2172..2183]:substance:"fatty acids"
;[2221..2224]:substance:"Cl-"
(SENT
  (S
    (NP-SBJ (DT:[2003..2008] These) (NNS:[2009..2016] results))
    (VP (VBP:[2017..2025] indicate)
      (SBAR (IN:[2026..2030] that)
        (S
          (NP-SBJ (NN:[2031..2040] carbachol))
          (VP
            (VP
              (ADVP (RB:[2041..2044] not) (RB:[2045..2049] only))
              (VBZ:[2050..2054] acts)
              (PP (IN:[2055..2057] as)
                (NP (DT:[2058..2059] a) (NN:[2061..2073] secretagogue))))
            (CC:[2074..2077] but)
            (VP
              (PP-TMP (IN:[2078..2080] at)
                (NP (DT:[2081..2084] the) (JJ:[2085..2089] same)
                    (NN:[2090..2094] time)))
              (VBZ:[2095..2106] initializes)
              (NP (NN:[2107..2121] downregulation))
              (PP-MNR (IN:[2122..2124] by)
                (NP
                  (S-NOM
                    (NP-SBJ (-NONE-:[2124..2124] *))
                    (VP (VBG:[2125..2135] increasing)
                      (NP
                        (NP (DT:[2136..2139] the)
                            (JJ:[2141..2154] intracellular)
                            (NN:[2155..2168] concentration))
                        (PP (IN:[2169..2171] of)
                          (NP (JJ:[2172..2177] fatty) (NNS:[2178..2183] acids))))))
                  (,:[2183..2184] ,)
                  (NP
                    (NP (DT:[2185..2186] a) (NN:[2187..2196] mechanism))
                    (VP (VBG:[2197..2205] limiting)
                      (NP (DT:[2206..2209] the) (VBG:[2210..2219] resulting)
                         (NN:[2221..2223] Cl) (SYM:[2223..2224] -)
                        (NN:[2225..2234] secretion)))))))))))
    (.:[2234..2235] .)))

;section 14 Span:2239..2284
;PMID: 11510894 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2239..2243] PMID) (::[2243..2244] :) (CD:[2245..2253] 11510894)
        (IN:[2254..2255] -LSB-) (NNP:[2255..2261] PubMed) (HYPH:[2262..2263] -)
        (JJ:[2264..2271] indexed) (IN:[2272..2275] for)
        (NNP:[2276..2284] MEDLINE-RSB-)))
